Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Bio-Europe Participation News
30
2024.10
Kangstem Biotech will participate in Bio Europe 2024, taking place from November 4 to 6 in Stockholm, Sweden. Leveraging domestic Phase I clinical data for its osteoarthritis treatment, OSCA, the company aims to initiate global commercialization efforts, including technology transfers with major international pharmaceutical firms.
Kangstem Biotech will participate in Bio Europe 2024, taking place from November 4 to 6 in Stockholm, Sweden. Leveraging domestic Phase I clinical data for its osteoarthritis treatment, OSCA, the company aims to initiate global commercialization efforts, including technology transfers with major international pharmaceutical firms.
We have already received requests for one-on-one partnering meetings from global pharmaceutical companies in various regions such as the United States, Japan, and China, including Big Pharma in Germany, France, and Switzerland, and have confirmed the schedule. Notably, with large pharmaceutical company specializing in regenerative medicine such as cartilage, tissue, and bone, we will hold specific business discussions based on the pain, function, and activity improvement and MRI image evaluation data of the OSCA Phase 1 clinical trial separately at the Swiss headquarters.
Business Development Headquarters of Kangstem Biotech said “Prior to the event, we held a preliminary meeting to enhance the understanding of OSCA, our advanced biofusion drug. We will continue these discussions to strengthen local partnerships and facilitate our entry into the global market," and “A key focus of this meeting will be to demonstrate to European pharmaceutical companies that previously viewed cartilage improvement and regeneration as unattainable. We will present the promising results from OSCA’s Phase I clinical trial, which include cartilage regeneration and enhancement of soft bone. We believe this will significantly impact our global business performance, including technology exports.”
As the world enters a super-aging era, the prevalence of osteoarthritis is rising rapidly, and the market is expanding accordingly. However, there is currently no DMOAD(disease-modifying osteoarthritis drug) available. In response, OSCA has garnered significant attention in the industry and market, as it aims to treat osteoarthritis through an intra-articular injection in the knee joint, eliminating the need for surgery.
In Phase I clinical trials, OSCA demonstrated a differentiated pain reduction effect and sustained results compared to existing drugs. The outcomes, which include cyst reduction, cartilage regeneration, and improvements in subchondral bone structure—linked to pain alleviation through MRI evaluations—are anticipated to position OSCA as a global innovative new drug.
The analysis of the Phase I clinical trial results is expected to be finalized in November. We plan to present these findings at the OARSI(International Osteoarthritis Society) conference in Songdo next April and at the ISAKOS(International Society for Arthroscopic Sports Knee Surgery) conference in Munich in June. Additionally, the Phase 2a clinical trial in Korea is accelerating with the approval of the IND change from the Ministry of Food and Drug Safety on the 24th.
https://news.mt.co.kr/mtview.php?no=2024103009003528047